Technical analysis of bioAffinity Technologies, Inc. (BIAF): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Price Performance
| 1 month | -24.65% |
| 3 months | -57.40% |
| Year-to-date | -69.77% |
| 1 year | -93.49% |
| 3 years | -99.29% |
52-Week Range
| 52-week High | $138.60 |
| 52-week Low | $4.56 |
| Avg Volume (90d) | 1.8M |
Technical Indicators
| SMA 50 | $8.48 |
| SMA 200 | $21.69 |
| Beta | -0.81 |
| 30-day Volatility (annualised) | 282.5% |
| Price vs SMA 50 | -36.9% |
| Price vs SMA 200 | -75.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $36.75 | |
| 2025-11 | $22.50 | -38.8% |
| 2025-12 | $17.70 | -21.3% |
| 2026-01 | $17.10 | -3.4% |
| 2026-02 | $15.90 | -7.0% |
| 2026-03 | $57.45 | +261.3% |
| 2026-04 | $37.35 | -35.0% |
| 2026-05 | $25.05 | -32.9% |
| 2026-06 | $12.18 | -51.4% |
| 2026-07 | $9.41 | -22.7% |
| 2026-08 | $4.56 | -51.5% |
| 2026-09 | $5.35 | +17.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $5.35 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.49 |
| EV / EBITDA | -0.19 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.38 |
| Current Ratio | 1.44 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -10.54 |